Reports: The Health Funds (Estonia): Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
Go back to [[Estonia]] page | Go back to [[Estonia]] page | ||
''' | '''Primary purpose:''' To outline the vision, mission, and strategic goals of the Health Insurance Fund in Estonia, focusing on ensuring the availability of health insurance benefits and improving healthcare services through prevention, early intervention, and better-coordinated treatment. | ||
''' | '''Sponsor, manager or home institution:''' [[dataOwner::Tervisekassa]]. | ||
'''Type of information:''' Health care costs; Medicine costs; Costs of disease prevention; Cancer screening costs; total health costs in general. [https://www.tervisekassa.ee/sites/default/files/Tervisekassa_2023_9kuu_aruanne.pdf Click here to learn more]. | |||
''' | '''Data level:''' [[dataLevel::national level]]. | ||
''' | '''Cancer areas of interest:''' [[hasCancerType::C15-C26: Digestive system cancers]]; [[hasCancerType::C30-C39: Lung/chest cancers]]; [[hasCancerType::C51-C58: Female genitalia cancer]]; [[hasCancerType::C50: Breast cancer]]. [https://www.tervisekassa.ee/sites/default/files/otsus_nr_267_Tervisekassa_Ipa_2022_aruanne.pdf Click here to learn more]. | ||
'''Access to information:''' | '''Access to information:''' [https://www.tervisekassa.ee/tervisekassa/finantsaruanded-ja-eelarve Click here to access]. | ||
Revision as of 14:08, 10 May 2024
Go back to Estonia page
Primary purpose: To outline the vision, mission, and strategic goals of the Health Insurance Fund in Estonia, focusing on ensuring the availability of health insurance benefits and improving healthcare services through prevention, early intervention, and better-coordinated treatment.
Sponsor, manager or home institution: Tervisekassa.
Type of information: Health care costs; Medicine costs; Costs of disease prevention; Cancer screening costs; total health costs in general. Click here to learn more.
Data level: national level.
Cancer areas of interest: C15-C26: Digestive system cancers; C30-C39: Lung/chest cancers; C51-C58: Female genitalia cancer; C50: Breast cancer. Click here to learn more.
Access to information: Click here to access.
